{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:23:37Z","timestamp":1784082217853,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jgo.2018.07.015","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T01:44:59Z","timestamp":1533865499000},"page":"411-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population"],"prefix":"10.1016","volume":"10","author":[{"given":"Joobin","family":"Sattar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Kartolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma M.","family":"Hopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua Matthew","family":"Lakoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Baetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2018.07.015_bb0005","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-0714","article-title":"FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma","author":"Beaver","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jgo.2018.07.015_bb0010","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-0712","article-title":"US FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab","author":"Hazarika","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11S","key":"10.1016\/j.jgo.2018.07.015_bb0015","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1016\/j.jtho.2016.09.088","article-title":"PS01.53: first-line atezolizumab plus Cancer immunotherapies in the elderly 577 chemotherapy in chemotherapy-naive patients with advanced NSCLC: a phase III clinical program: topic: medical oncology","volume":"11","author":"Jotte","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2018.07.015_bb0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2018.07.015_bb0025","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jgo.2018.07.015_bb0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/2229-3485.167099","article-title":"Elderly patients' participation in clinical trials","volume":"6","author":"Shenoy","year":"2015","journal-title":"Perspect Clin Res"},{"issue":"22","key":"10.1016\/j.jgo.2018.07.015_bb0035","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2004.02.175","article-title":"Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration","volume":"22","author":"Talarico","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2018.07.015_bb0040","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0531-5565(96)00152-0","article-title":"The aging immune system: primary and secondary alterations of immune reactivity in the elderly","volume":"32","author":"Wick","year":"1997","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.jgo.2018.07.015_bb0045","first-page":"537","article-title":"Aging, immunity, and cancer","volume":"11","author":"Fulop","year":"2011","journal-title":"Discov Med"},{"issue":"4","key":"10.1016\/j.jgo.2018.07.015_bb0050","first-page":"219","article-title":"Cancer immunotherapy in older patients","volume":"23","author":"Marrone","year":"2017","journal-title":"Cancer J"},{"key":"10.1016\/j.jgo.2018.07.015_bb0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2249.1992.tb07954.x","article-title":"Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population","volume":"90","author":"Paganelli","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jgo.2018.07.015_bb0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cellimm.2017.02.001","article-title":"Influence of age, sex and HCMV-serostatus on blood lymphocyte subpopulations in healthy adults","volume":"314","author":"Apoil","year":"2017","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jgo.2018.07.015_bb0065","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.exger.2003.12.016","article-title":"Age related microsatellite instability in T cells from healthy individuals","volume":"39","author":"Krichevsky","year":"2004","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.jgo.2018.07.015_bb0070","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0167-5699(00)01714-X","article-title":"Ageing of lymphocytes and lymphocytes in the aged","volume":"21","author":"Globerson","year":"2000","journal-title":"Immunol Today"},{"key":"10.1016\/j.jgo.2018.07.015_bb0075","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.critrevonc.2007.03.002","article-title":"Aging and the dendritic cell system: implications for cancer","volume":"64","author":"Shurin","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jgo.2018.07.015_bb0080","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.arr.2013.04.003","article-title":"The impact of ageing on natural killer cell function and potential consequences for health in older adults","volume":"12","author":"Hazeldine","year":"2013","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.jgo.2018.07.015_bb0085","first-page":"340","article-title":"Increased number of circulating Leu 11+ (CD 16) large granular lymphocytes and decreased NK activity during human ageing","volume":"68","author":"Facchini","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jgo.2018.07.015_bb0090","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood.V92.7.2410","article-title":"Age-related decline of perforin expression in human cytotoxic T lymphocytes and natural killer cells","volume":"92","author":"Rukavina","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2018.07.015_bb0095","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1189\/jlb.1103592","article-title":"Aging and innate immune cells","volume":"76","author":"Plackett","year":"2004","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jgo.2018.07.015_bb0100","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.4049\/jimmunol.176.11.6586","article-title":"CD4+ CD25+ Foxp3+ T cells and CD4+ CD25-Foxp3+ T cells in aged mice","volume":"176","author":"Nishioka","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jgo.2018.07.015_bb0105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40266-017-0479-1","article-title":"Cancer immunotherapies: are they as effective in the elderly?","volume":"34","author":"Poropatich","year":"2017","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jgo.2018.07.015_bb0110","first-page":"149","article-title":"Reviewing the definition of \u201celderly\u201d","volume":"6","author":"Orimo","year":"2006","journal-title":"GeriatrGerontol Int"},{"key":"10.1016\/j.jgo.2018.07.015_bb0115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.56.2.4","article-title":"Aging biology and geriatric clinical pharmacology","volume":"56","author":"McLean","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jgo.2018.07.015_bb0120","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jgo.2018.07.015_bb0125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.jgo.2018.07.015_bb0130","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Yang J.C., Atkins M.B., &Disis M.L. toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2018.07.015_bb0135","doi-asserted-by":"crossref","first-page":"lv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2018.07.015_bb0140","author":"National Cancer Institute"},{"issue":"5","key":"10.1016\/j.jgo.2018.07.015_bb0190","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"11","key":"10.1016\/j.jgo.2018.07.015_bb0195","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.jgo.2018.07.015_bb0145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.ackd.2015.08.004","article-title":"Structural and functional changes with the aging kidney","volume":"23","author":"Denic","year":"2016","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"10.1016\/j.jgo.2018.07.015_bb0150","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.ackd.2010.05.002","article-title":"The aging kidney: physiological changes","volume":"17","author":"Weinstein","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"10.1016\/j.jgo.2018.07.015_bb0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/cts.12391","article-title":"Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities","volume":"9","author":"Morrissey","year":"2016","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jgo.2018.07.015_bb0160","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jgo.2016.05.007","article-title":"The development of immunotherapy in older adults: new treatments, new toxicities?","volume":"7","author":"Helissey","year":"2016","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2018.07.015_bb0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/2051-1426-3-S2-P133","article-title":"Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma","volume":"3","author":"Freeman","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.jgo.2018.07.015_bb0170","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1615\/CritRevOncog.2013010591","article-title":"Optimization of immunotherapy in elderly cancer patients","volume":"18","author":"Tomihara","year":"2013","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.jgo.2018.07.015_bb0175","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2017.05.044","article-title":"Immune checkpoint inhibitors and elderly people: a review","volume":"82","author":"Daste","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jgo.2018.07.015_bb0180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrclinonc.2013.245","article-title":"Mitigating the toxic effects of anticancer immunotherapy","volume":"11","author":"Gangadhar","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"suppl_4","key":"10.1016\/j.jgo.2018.07.015_bb0185","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940681830064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940681830064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:50:09Z","timestamp":1761817809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187940681830064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S187940681830064X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2018.07.015","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2018.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}